The Bardo Foundation is proud to announce our partnership with the Myrovlitis Trust in funding a very promising childhood cancer research project.
This research, led by Professor Nancy DeMore of the Medical University of South Carolina, focuses on the development of a combination therapy for metastatic osteosarcoma. The therapy involves the use of a humanized monoclonal antibody, which targets and destroys the cancer cells in the body. This new treatment is designed to work in combination with existing chemotherapy drugs, offering a more effective and efficient way to treat childhood cancer.
We believe that investing in medical research is crucial in the fight against childhood cancer. That is why we are honored to support Professor DeMore and her team in their efforts to find a cure. Their work has the potential to greatly improve the treatment and cure of childhood cancer, offering hope and a brighter future for children and their families.
At The Bardo Foundation, we are committed to making a positive difference in the lives of those affected by childhood cancer. Our partnership with the Myrovlitis Trust and support of this research project is just one example of our commitment to finding a cure for this devastating illness.
We are confident that Professor DeMore and her team will make a significant impact in the fight against childhood cancer and we are proud to support their efforts. We hope that the results of this research will lead to new and improved treatments for children with metastatic osteosarcoma, offering them a brighter future and a better chance at recovery.